Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	USD 1.190	+2.59%	11,767,489
23/07/26	USD 1.160	-8.66%	3,732,613
22/07/26	USD 1.270	-7.97%	1,990,449
21/07/26	USD 1.380	-4.17%	2,181,809
20/07/26	USD 1.440	-8.86%	1,718,822

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.190USD

Average target price

4.000USD

Spread / Average Target

+236.13%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 06:00:00 25/07/26 am AEST			5-day change	1st Jan Change
1.190 ^USD	+2.59%		-24.68%	-48.93%

15/07	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ
14/07	Innovent Biologics, Inc. and Spero Therapeutics, Inc. Announce Exclusive License Agreement for IBI355, Phase 2-Ready Third-Generation Anti-CD40L Antibody	CI

Market Cap	68.9M 60.52M 56.28M 51.64M 97.04M 6.64B 98.53M 668M 261M 3.26B 259M 253M 11.28B	P/E 2024	-0.81x	P/E 2025	15.5x
Enterprise Value	68.9M 60.52M 56.28M 51.64M 97.04M 6.64B 98.53M 668M 261M 3.26B 259M 253M 11.28B	EV / Sales 2024	1,170,430x	EV / Sales 2025	-
Free-Float	77.54%	Yield 2024 *	-	Yield 2025	-

15/07	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ
14/07	Innovent Biologics, Inc. and Spero Therapeutics, Inc. Announce Exclusive License Agreement for IBI355, Phase 2-Ready Third-Generation Anti-CD40L Antibody	CI
14/07	Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing	MT
14/07	Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion	RE
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Benchmark	CI
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Index	CI
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Index	CI
29/06	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index	CI
18/06	GSK says US FDA approves urinary tract infection treatment Utebzi	AN
18/06	GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections	CI
18/06	GSK Secures US FDA Nod for Complicated Urinary Tract Infection Antibiotic	MT
18/06	GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections	MT
18/06	GSK, Spero Therapeutics Gain U.S. Approval for Utebzi	DJ

21/10/25	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
21/12/24	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
19/11/24	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
07/08/24	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
14/08/23	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT

Spero Therapeutics, Inc. Stock

Stocks

SPRO

US84833T1034

Biotechnology & Medical Research

Valuation: Spero Therapeutics, Inc.

Chart: Spero Therapeutics, Inc.

Latest news : Spero Therapeutics, Inc.

Last Transcript: Spero Therapeutics, Inc.

Analysts' recommendations: Spero Therapeutics, Inc.

Press Releases: Spero Therapeutics, Inc.

News in other languages: Spero Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Spero Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

14/07	Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties	AQ
14/07	Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody	AQ
14/05	Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update	AQ
06/05	Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026	AQ
27/03	Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update	AQ

18/06	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
18/06	Star Warsh
18/06	MORNING BRIEFING - Deutschland/Europa -2-
18/06	GSK und Spero Therapeutics erhalten US-Zulassung für Utebzi
21/10/25	GSK et Spero publient des résultats positifs sur un antibiotique expérimental

1 day	+2.59%
1 week	-24.68%
Current month	-46.15%
1 month	-47.35%
3 months	-56.57%
6 months	-51.43%
Current year	-48.93%

1 week	1.08	1.44
1 month	1.08	2.34
Current year	1.08	3.08
1 year	1.08	3.08
3 years	0.51	3.22
5 years	0.51	19.87
10 years	0.51	23.64

Manager	Title	Age	Since
Esther Rajavelu CEO	Chief Executive Officer	47	10/01/2025
Timothy Keutzer COO	Chief Operating Officer	58	01/02/2023
Shai Biran IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Milind Deshpande CHM	Chairman	69	01/01/2014
Patrick Volkert Vink BRD	Director/Board Member	62	01/09/2015
Frank Thomas CHM	Chairman	56	10/01/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/6/26	Milind Deshpande	Free	Director	30,000	0.0518%
23/6/26	Patrick Volkert Vink	Free	Director	30,000	0.0518%
23/6/26	Frank Thomas	Free	Chairman	30,000	0.0518%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPERO THERAPEUTICS, INC.	+2.59%	-24.68%	-48.93%	-16.20%	68.9M
ARGENX SE	+0.93%	+6.97%	+59.60%	+69.78%	57.28B
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+40.64%	+80.66%	54.99B
INSMED INCORPORATED	-0.46%	-1.29%	+2.86%	+425.15%	23.18B
BIONTECH SE	-2.97%	-2.35%	-22.53%	-15.34%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	-1.23%	+0.78%	+20.50%	-7.97%	20.46B
GENMAB A/S	-1.34%	+0.51%	+26.03%	-28.68%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.68%	+2.18%	+34.82%	+547.80%	15.67B
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+170.77%	+310.94%	14.46B
EXELIXIS, INC.	-0.50%	-0.98%	+21.43%	+179.36%	13.92B
Average	-0.62%	-1.32%	+30.52%	+154.55%	24.02B
Weighted average by Cap.	-0.85%	+2.09%	+39.11%	+136.76%

	2024	2025
Net sales	47.98M 42.14M 39.19M 35.96M 67.57M 4.62B 68.61M 465M 182M 2.27B 180M 176M 7.85B	66.8M 58.67M 54.56M 50.07M 94.08M 6.43B 95.53M 648M 253M 3.16B 251M 245M 10.94B
Net income	-68.57M -60.22M -56M -51.39M -96.56M -6.6B -98.05M -665M -260M -3.25B -257M -252M -11.22B	8.57M 7.53M 7M 6.42M 12.07M 825M 12.26M 83.14M 32.48M 406M 32.18M 31.49M 1.4B
Net Debt	-	-